Cutaneous T-cell lymphoma's confounding nature.
Charlie
C
Schmidt
D000368:Aged; D000074323:Alemtuzumab; D000630:Aminopterin / Q000008:administration & dosage / Q000031:analogs & derivatives; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077610:Bexarotene; D000079963:Brentuximab Vedotin; D057210:Delayed Diagnosis; D003937:Diagnosis, Differential; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000188:drug therapy; D012074:Remission Induction; D012751:Sezary Syndrome / Q000175:diagnosis / Q000188:drug therapy; D033581:Stem Cell Transplantation; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage; D014184:Transplantation, Homologous
C418863:10-propargyl-10-deazaaminopterin; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D013764:Tetrahydronaphthalenes; D000074323:Alemtuzumab; D000079963:Brentuximab Vedotin; D000077610:Bexarotene; D000630:Aminopterin